Inhibition or/and induction of CYP3A4 are the major mechanisms underlying the common   clinical drug-drug interactions, which has been gained attention in new drug discovery and development as well as clinical practice.  Quantitative prediction of drug-drug interactions at the early stage of drug development is advantageous for reducing the cost and duration of development and providing more information for the later clinical studies.  The review summarizes the update progress on quantitative prediction of in vivo drug-drug  interactions derived from models based on in vitro inhibition or/and induction for CYP3A4.